Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology

Blohmer, Martin; Zhu, Li; Atkinson, Jennifer M.; Beriwal, Sushil; Rodríguez‐López, Joshua L.; Rosenzweig, Margaret; Brufsky, Adam; Tseng, George C.; Lucas, Peter C.; Lee, Adrian V.; Oesterreich, Steffi; Jankowitz, Rachel C.

doi:10.1186/s13058-020-01309-3

Cited by 18 publications

(21 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An earlier study of Mathew et al found that after diagnosis of distant metastasis, there was no outcome difference between ILC and IDC, 38 while the study of Blohmer et al showed that, after diagnosis of the first distant metastasis, survival was much shorter for ILC patients than IDC patients. 39 The Cancer Genome Atlas (TCGA) research network recently published results of genomic characterization of 490 IDC and 127 ILC breast cancer cases. 2 , 40 As expected, ILC was prone to luminal A subtype, CDH1 mutations, and loss of E-cadherin by mRNA expression.…”

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics and Survival Outcomes of Infiltrating Lobular Carcinoma: A Retrospective Study of 365 Cases in China

Han¹,

Gu²,

Liu³

et al. 2022

CMAR

View full text Add to dashboard Cite

The objective of this study was to compare the demographic characteristics, clinicopathological factors and survival outcomes between infiltrating lobular carcinoma (ILC) and infiltrating ductal carcinoma (IDC) using our single-center database. Methods: Seventeen thousand two hundred and three breast cancer patients were treated at Fudan University Shanghai Cancer Center (FUSCC) from January 2000 to December 2017. We identified 365 cases with ILC and 16,838 cases with IDC. The Pearson chi-square test was used to compare tumor characteristics, and the Kaplan-Meier methods were used to perform the survival analysis. Results: ILC had some distinctive characteristics from IDC such as older age (ranged from 61 to 80: ILC 26.8% vs IDC 19.9%, P < 0.001; over 80: ILC 1.6% vs IDC 0.8%, P < 0.001), larger tumor size (ranged from 2 to 5: ILC 45.2% vs IDC 37.1%, P = 0.011), much more hormone receptor expression (ILC 92.9% vs IDC 73.0%, P < 0.001), extremely less HER-2 expression (ILC 7.1% vs IDC 25.9%, P < 0.001). The overall survival and disease-free survival of ILC were worse than IDC (5-year OS, ILC 93.6% vs IDC 94.5%, P < 0.001; 5-year DFS, ILC 88.5% vs IDC 91.6%, P = 0.008). It was worth noting that the ILC patients had a worse overall survival than IDC patients after our propensity score matching study (P = 0.037). The univariate analysis concluded that positive HR (hormone receptor), high expression of Ki-67 and higher pathologic tumor stage were poor prognostic markers of ILC. Multivariate analysis demonstrated that tumor stage was a poor prognostic marker after adjustment for the effects of the above three factors. The most common primary site of metastasis was bone, but the proportion in the ILC group was much higher than that in the IDC group (56.25% vs 36.40%, P = 0.003). Conclusion: Compared with IDC, ILC survived worse and was more prone to bone metastasis. Therefore, a comprehensive understanding of ILC and specific treatments are needed for further research.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics and Survival Outcomes of Infiltrating Lobular Carcinoma: A Retrospective Study of 365 Cases in China

Han¹,

Gu²,

Liu³

et al. 2022

CMAR

View full text Add to dashboard Cite

show abstract

“…In spite of clear biological differences (e.g., sites of metastases), ILC is currently managed in the clinic in the same fashion as grade and stage-matched invasive breast cancer of no special type (IBC-NST). While prognosis over the short term is good, it is increasingly clear that ILC patients do worse than IBC-NST (grade-dependent) over time [ 3 , 4 ], and are more likely to metastasize to unusual sites, such as gynaecological and gastrointestinal organs, than IBC-NST [ 5 , 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

The Genomic Landscape of Lobular Breast Cancer

Reed

Foong

Kutasovic

et al. 2021

Cancers

View full text Add to dashboard Cite

Invasive lobular carcinoma (ILC) is the second most common breast cancer histologic subtype, accounting for approximately 15% of all breast cancers. It is only recently that its unique biology has been assessed in high resolution. Here, we present a meta-analysis of ILC sequencing datasets, to provide a long-awaited ILC-specific resource, and to confirm the prognostic value and strength of association between a number of clinico-pathology features and genomics in this special tumour type. We consider panel (n = 684), whole exome (n = 215) and whole genome sequencing data (n = 48), and review histology of The Cancer Genome Atlas cases to assign grades and determine whether the ILC is of classic type or a variant, such as pleomorphic, prior to performing statistical analyses. We demonstrate evidence of considerable genomic heterogeneity underlying a broadly homogeneous tumour type (typically grade 2, estrogen receptor (ER)-positive); with genomes exhibiting few somatic mutations or structural alterations, genomes with a hypermutator phenotype, and tumours with highly rearranged genomes. We show that while CDH1 (E-cadherin) and PIK3CA mutations do not significantly impact survival, overall survival is significantly poorer for patients with a higher tumour mutation burden; this is also true for grade 3 tumours, and those carrying a somatic TP53 mutation (and these cases were more likely to be ER-negative). Taken together, we have compiled a meta-dataset of ILC with molecular profiling, and our analyses show that the genomic landscape significantly impacts the tumour’s variable natural history and overall survival of ILC patients.

show abstract

“…For example, numerous case reports of ILC seeding as orbital metastases appear to suggest these are more likely to arise from an ILC than other types, and in a sole example of a mixed ductal-lobular carcinoma, only the lobular component was found in the orbital metastasis (e.g. [19][20][21][22]).…”

Section: Introductionmentioning

confidence: 99%

Invasive lobular carcinoma of the breast: the increasing importance of this special subtype

et al. 2021

View full text Add to dashboard Cite

Invasive lobular carcinoma (ILC) is the most common of the breast cancer special types, accounting for up to 15% of all breast cancer cases. ILCs are noted for their lack of E-cadherin function, which underpins their characteristic discohesive growth pattern, with cells arranged in single file and dispersed throughout the stroma. Typically, tumours are luminal in molecular subtype, being oestrogen and progesterone receptor positive, and HER2 negative. Since last reviewing the lobular literature (McCart Reed et al., Breast Cancer Res 17:12, 2015), there has been a considerable increase in research output focused on this tumour type, including studies into the pathology and management of disease, a high-resolution definition of the genomic landscape of tumours as well as the evolution of several potential therapeutic avenues. There abounds a huge amount of new data, which we will review herein.

show abstract

Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology

Cited by 18 publications

References 30 publications

Clinical Characteristics and Survival Outcomes of Infiltrating Lobular Carcinoma: A Retrospective Study of 365 Cases in China

Clinical Characteristics and Survival Outcomes of Infiltrating Lobular Carcinoma: A Retrospective Study of 365 Cases in China

The Genomic Landscape of Lobular Breast Cancer

Invasive lobular carcinoma of the breast: the increasing importance of this special subtype

Contact Info

Product

Resources

About